The srRNA vaccine is taken up by APCs, which present neoantigen peptides and expand neoantigen-specific T cells. These T cells recognize neoantigen peptide–MHC complexes (including HLA class II–restricted) on tumor cells and kill them via perforin/granzyme-mediated cytotoxicity.